Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)

$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd at NWR Healthcare Conference (Virtual) Transcript
Mar 22, 2023
Paradigm Biopharmaceuticals Ltd Annual Shareholders Meeting Transcript
Nov 29, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Oct 04, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Aug 15, 2022
Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript
Jul 21, 2022
Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Paradigm Biopharmaceuticals Ltd Corporate Call Transcript
Aug 05, 2021
Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Paradigm Biopharmaceuticals Ltd Inaugural R&D Day Transcript
Dec 21, 2020
Paradigm Biopharmaceuticals Ltd Investor Call (Virtual) Transcript
Apr 08, 2020
Paradigm Biopharmaceuticals Ltd at NWR Communications Virtual Small Cap Investor Conference Transcript
Mar 26, 2020

Paradigm Biopharmaceuticals Ltd Investor Call (Virtual) Transcript

Apr 08, 2020 / NTS GMT

Release Date Price: $0.86

Transcript

Operator

Thank you for standing by, and welcome to the Paradigm Biopharmaceuticals investor conference call. I would now like to hand the conference over to Mr. Paul Rennie, CEO. Please go ahead, Paul.

Paul Rennie

Paradigm Biopharmaceuticals Limited - MD

Thank you very much, and thank you, everyone, for attending. And I'd also like to make a special note of thanks to our investors from Asia and also the United States who dialed into the call this morning. The purpose of the call is to really inform everybody of a large amount of information that we've released in the last few days. We've had quite a number of ASX announcements in relation to the trading halt and then information in relation to the minutes of the FDA meeting. And then we had the minutes or an update in terms of the exciting new data that we have from 34 special access cases and so on.

And today, we'll be making announcements around the conclusion of the capital raise, so a lot of information is going out. And I just really wanted to try and walk everyone through the key aspects of all of that. And

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.